Skip to main content

Table 1 Demographic and clinical variables in healthcare subjects and patients with or without diabetic foot

From: Assessment of heart rate variability (HRV) in subjects with type 2 diabetes mellitus with and without diabetic foot: correlations with endothelial dysfunction indices and markers of adipo-inflammatory dysfunction

Variables

DFS (n = 63)

NDFS (n = 30)

Healthy (n = 30)

pa

Sex M/F

45/18

11/19

14/16

0.003

Hypertension (n/%)

58/92

24/80

14/46

 < 0.0005

Cardiovascular events (n/%)

24/38

12/40

20/66

0.028

Stroke (n/%)

13/20

4/13

3/10

0.380

Dyslipidemia (n/%)

45/71

18/60

24/80

0.231

Smoker (n/%)

23/36

10/33

25/83

 < 0.0005

Beta blocker (n/%)

20/31

13/43

12/40

0.503

Calcium channel blocker (n/%)

27/42

13/43

12/40

0.958

ACE inhibitor or ARBs (n/%)

26/41

13/43

12/40

0.965

Statin (n/%)

47/74

20/66

25/83

0.331

Antiplatelet (n/%)

28/44

10/33

13/43

0.580

GLP-1 agonist or DPP4 inhibitors (n/%)

1/1

5/16

0/0

0.002

Sulfonylurea (n/%)

1/1

11/36

0/0

 < 0.0005

Metformin (n/%)

10/15

16/53

0/0

 < 0.0005

Insulin (n/%)

63/100

6/20

0/0

 < 0.0005

  1. DFS, diabetes foot syndrome; ARBs, Angiotensin II receptor blockers
  2. GLP-1: Glucagon-like peptide-1 receptor; DPP4 inhibitors, Inhibitors of dipeptidyl peptidase 4
  3. ap, intergroup differences among patient groups (chi-square test or Fisher’s test, as needed)
Back to article page

Cardiovascular Diabetology

ISSN: 1475-2840